Overview

To Study the Oral Bioavailability of a New Combination Formation of Decitabine and Tetrahydrouridine in Healthy Males

Status:
Recruiting
Trial end date:
2023-06-10
Target enrollment:
Participant gender:
Summary
This is an open-label, randomized, single-dose per period, two-period, crossover study to evaluate the relative bioavailability of decitabine and tetrahydrouridine ingested as a modified-release combination formulation compared to THU and decitabine ingested as immediate-release capsules
Phase:
Phase 1
Details
Lead Sponsor:
EpiDestiny, Inc.
Collaborator:
Worldwide Clinical Trials
Treatments:
Decitabine
Tetrahydrouridine